CTNM
Contineum·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 0
Consensus Rating "Buy"
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CTNM
Contineum Therapeutics, Inc.
A clinical-stage biotechnology company focused on the fields of neurology, inflammation, and immunology.
Chemical and pharmaceutical
--
04/05/2024
NASDAQ Stock Exchange
51
12-31
Common stock
3565 General Atomics Court, Suite 200, San Diego, California 92121
Develops therapies for neurological and immunology indications.
Contineum Therapeutics, Inc., was incorporated in Delaware in 2009 as Versense Pharmaceuticals, Inc., and adopted its current name in November 2023 after several mergers and name changes. The Company is a clinical-stage biopharmaceutical company focused on the development of differentiated oral small molecule therapies for neuroinflammatory and immunological indications with significant unmet needs. Its product line includes the wholly-owned drug candidate PIPE-791 for idiopathic pulmonary fibrosis and chronic pain, and the co-developed drug candidate PIPE-307 for depression and multiple sclerosis.
Company Financials
EPS
CTNM has released its 2026 Q2 earnings. EPS was reported at -0.4, versus the expected -0.45, beating expectations. The chart below visualizes how CTNM has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
